Your browser doesn't support javascript.
loading
SHLD2/FAM35A co-operates with REV7 to coordinate DNA double-strand break repair pathway choice.
Findlay, Steven; Heath, John; Luo, Vincent M; Malina, Abba; Morin, Théo; Coulombe, Yan; Djerir, Billel; Li, Zhigang; Samiei, Arash; Simo-Cheyou, Estelle; Karam, Martin; Bagci, Halil; Rahat, Dolev; Grapton, Damien; Lavoie, Elise G; Dove, Christian; Khaled, Husam; Kuasne, Hellen; Mann, Koren K; Klein, Kathleen Oros; Greenwood, Celia M; Tabach, Yuval; Park, Morag; Côté, Jean-Francois; Masson, Jean-Yves; Maréchal, Alexandre; Orthwein, Alexandre.
Afiliação
  • Findlay S; Lady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
  • Heath J; Division of Experimental Medicine, McGill University, Montreal, QC, Canada.
  • Luo VM; Lady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
  • Malina A; Division of Experimental Medicine, McGill University, Montreal, QC, Canada.
  • Morin T; Lady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
  • Coulombe Y; Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada.
  • Djerir B; Lady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
  • Li Z; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada.
  • Samiei A; Department of Biology, Université de Sherbrooke, Sherbrooke, QC, Canada.
  • Simo-Cheyou E; Genome Stability Laboratory, CHU de Québec Research Center, Quebec City, QC, Canada.
  • Karam M; Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, Quebec City, QC, Canada.
  • Bagci H; Department of Biology, Université de Sherbrooke, Sherbrooke, QC, Canada.
  • Rahat D; Lady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
  • Grapton D; Lady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
  • Lavoie EG; Division of Experimental Medicine, McGill University, Montreal, QC, Canada.
  • Dove C; Lady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
  • Khaled H; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada.
  • Kuasne H; Division of Experimental Medicine, McGill University, Montreal, QC, Canada.
  • Mann KK; Institut de Recherches Cliniques de Montréal (IRCM), Montreal, QC, Canada.
  • Klein KO; Department of Anatomy and Cell Biology, McGill University, Montreal, QC, Canada.
  • Greenwood CM; Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University of Jerusalem, Jerusalem, Israel.
  • Tabach Y; Lady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
  • Park M; Lady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
  • Côté JF; Lady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
  • Masson JY; Division of Experimental Medicine, McGill University, Montreal, QC, Canada.
  • Maréchal A; Lady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
  • Orthwein A; Division of Experimental Medicine, McGill University, Montreal, QC, Canada.
EMBO J ; 37(18)2018 09 14.
Article em En | MEDLINE | ID: mdl-30154076
ABSTRACT
DNA double-strand breaks (DSBs) can be repaired by two major pathways non-homologous end-joining (NHEJ) and homologous recombination (HR). DNA repair pathway choice is governed by the opposing activities of 53BP1, in complex with its effectors RIF1 and REV7, and BRCA1. However, it remains unknown how the 53BP1/RIF1/REV7 complex stimulates NHEJ and restricts HR to the S/G2 phases of the cell cycle. Using a mass spectrometry (MS)-based approach, we identify 11 high-confidence REV7 interactors and elucidate the role of SHLD2 (previously annotated as FAM35A and RINN2) as an effector of REV7 in the NHEJ pathway. FAM35A depletion impairs NHEJ-mediated DNA repair and compromises antibody diversification by class switch recombination (CSR) in B cells. FAM35A accumulates at DSBs in a 53BP1-, RIF1-, and REV7-dependent manner and antagonizes HR by limiting DNA end resection. In fact, FAM35A is part of a larger complex composed of REV7 and SHLD1 (previously annotated as C20orf196 and RINN3), which promotes NHEJ and limits HR Together, these results establish SHLD2 as a novel effector of REV7 in controlling the decision-making process during DSB repair.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas de Ciclo Celular / Proteínas de Ligação a DNA / Quebras de DNA de Cadeia Dupla / Reparo do DNA por Junção de Extremidades / Proteínas Mad2 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas de Ciclo Celular / Proteínas de Ligação a DNA / Quebras de DNA de Cadeia Dupla / Reparo do DNA por Junção de Extremidades / Proteínas Mad2 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article